Faroalfa/SR

Faroalfa/SR (Faropenem sodium) is an oral broad-spectrum antibiotic from penem group. It is the only penem available currently for oral administration, which shares structural similarities with both penicillins and cephalosporins. It is active against both gram-positive and gram-negative aerobes and anaerobes. Faropenem is resistant to hydrolysis by nearly all beta-lactamases, including extended-spectrum all beta-lactamases and AmpC beta-lactamases. It has a low chance for resistance development and beta-lactamase induction. This makes it attractive for the treatment of community-acquired infections, and for sequential therapy following carbapenem treatment without threatening the activity of carbapenems or the entire beta-lactam class in the hospital environment. It is approved for use in the treatment of upper and lower respiratory tract infections, ear, nose and throat (ENT) infections, genito-urinary infections, skin and skin structure infections, and gynaecological infections. Faropenem is a very promising and new oral antibiotic with proven efficacy and safety for the treatment of a variety of community-acquired infections.